I don't know who writes the Siemens press releases but I tend to find them interesting and instructive, particularly when compared to those of other companies. A recent story coinciding with the company's participation at the CLMA conference was no exception to this rule (see: Siemens Medical Solutions Diagnostics Showcases at CLMA Thinklab 2007). For background reading, you may want to refer to my previous notes discussing Siemens' recent IVD acquisitions and strategic initiatives. This most recent press article helps fill in some of the gaps regarding the company's current strategic goals. Below is an excerpt from it:
Key business areas [for Siemens Medical Solutions Diagnostics] include: laboratory testing and laboratory automation, enhancing the ability to detect, monitor and manage disease as well as point-of-care systems for urinalysis, blood gas and diabetes testing....The First Full Service Diagnostic Company....Siemens Medical Solutions Diagnostics is in the unique position to offer laboratory diagnostics, diagnostic imaging and clinical information under one roof. The company is working to deliver solutions that support early detection, enable diagnosis with in-vitro and in-vivo testing, and help to monitor treatment progress....The company's products and services bring together the right balance of science, technology, and practicality across the healthcare continuum to empower medical professionals with the vital information they need to deliver better, more personalized healthcare to patients around the globe.
I have the following comments about this article:
- I like the reference above to the corporate goal of seeking to detect, monitor, and manage disease. This short but concise mantra clearly articulates where the company is headed in the healthcare industry. Obviously, this is also a very broad objective that covers the entire spectrum of care with the exception of treatment. Note also the later reference in the article to positioning the company across the healthcare continuum that reinforces this broad sweep of interest.
- I was also struck by the company's declaration of offering laboratory diagnostics, diagnostic imaging and clinical information under one roof. This imagery of one roof is compelling from a marketing perspective, particularly in an era of fragmentation and lack of continuity that is encountered in many companies.
- Note also the reference above to early detection. Siemens here is taking a leaf from the playbook of GE that has begun to popularize the so-called early health model that I have discussed in detail in other notes.
- Finally, there is the reference to personalized healthcare that also conjures up the notion of personalized medicine that has been discussed here previously. Implicit in the term personalized healthcare is the promise of higher service to lab professionals but also the value of molecular diagnostics in choosing more effective therapeutic agents for patients.